Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Valerie Smith-Gamble

Geriatric Psychiatry Murfreesboro, TN Medical Doctor

NPI 1265483101 CMS profile 1168551

3400 Lebanon Rd, Murfreesboro, TN 37129

Open in the dashboard

General payments

$959

36 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Valerie Smith-Gamble of Murfreesboro, TN is reported in the CMS Open Payments database as having received $959 across 36 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Geriatric Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $232 9
2024 General $260 11
2023 General $273 10
2022 General $178 5
2021 General $16 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Valerie Smith-Gamble
  • Geriatric Psychiatry median
  • Middle half of Geriatric Psychiatry
  • National median

In program year 2025, general payments to Valerie Smith-Gamble were reported at $232. Among 188 Geriatric Psychiatry profiles paid that year, the median was $125 and the middle half received between $52 and $515.

Show as a table
Year Valerie Smith-Gamble Geriatric Psychiatry median Middle half National median
2019 $0 $151 $47–$484 $163
2020 $0 $112 $30–$410 $114
2021 $16 $122 $35–$550 $132
2022 $178 $133 $54–$557 $149
2023 $273 $138 $61–$485 $160
2024 $260 $127 $51–$572 $164
2025 $232 $125 $52–$515 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Neurocrine Biosciences, Inc. $234 7 payments
  2. Teva Pharmaceuticals USA, Inc. $225 10 payments
  3. Alkermes, Inc. $123 2 payments
  4. Otsuka America Pharmaceutical, Inc. $64 3 payments
  5. AbbVie, Inc. $63 4 payments
  6. Janssen Pharmaceuticals, Inc $62 2 payments
  7. Lundbeck LLC $29 1 payment
  8. ITI, Inc. $28 1 payment
  9. E.R. Squibb & Sons, L.L.C. $27 1 payment
  10. Tempus AI, Inc $26 1 payment
  11. Other $77 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $959 36 payments
Products named General payments · program years 2021–2025
  1. INGREZZA $234 7 payments
  2. Austedo XR $200 9 payments
  3. LYBALVI Cns $65 1 payment
  4. LYBALVI Cns $65 1 payment
  5. LYBALVI Cns $65 1 payment
  6. LYBALVI Cns $65 1 payment
  7. REXULTI $64 3 payments
  8. VRAYLAR $63 4 payments
  9. ARISTADA Cns $58 1 payment
  10. ARISTADA Cns $58 1 payment
  11. Other $479 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

1,385

Median for Neuropsychiatry: 88

Drug cost

$310,456

Median for Neuropsychiatry: $2,689

Branded share of claims

18.2%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 22 $140,627
Ingrezza Valbenazine Tosylate Brand 14 $106,723
Rexulti Brexpiprazole Brand 17 $25,121
Lurasidone Hcl Generic 19 $6,942
Chlorpromazine Hcl Generic 16 $4,738
Memantine Hcl Er Memantine Hcl Brand 18 $2,823
Bupropion Xl Bupropion Hcl Brand 47 $1,935
Quetiapine Fumarate Er Quetiapine Fumarate Brand 23 $1,558
Aripiprazole Generic 55 $1,499
Duloxetine Hcl Generic 75 $1,409

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $113
$113 22 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $35
  • Lundbeck LLC $29
$63 17 —
CAPLYTA
  • ITI, Inc. $28
$28 — —
VRAYLAR
  • AbbVie, Inc. $19
$19 — —
ABILIFY MAINTENA
  • Otsuka America Pharmaceutical, Inc. $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

36 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Psychiatry in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record